Synergistic Effects of Combining Anti-Midkine and Hepatocyte Growth Factor Therapies Against Diabetic Nephropathy in Rats.

摘要: Abstract: Purpose This study aimed to assess whether synergism could be achieved when combining midkine (MK) antisense oligodeoxynucleotides (anti-MK ODN) and recombinant human hepatocyte growth factor (HGF) in diabetic nephropathy (DN) rat models. Methods Rats were randomized into 6 groups: control, DN rats without treatment, treated with scrambled ODN, anti-MK HGF ODN plus HGF. models created by intraperitoneal injection of streptozotocin. Two weeks later, treatments commenced. (1 mg/kg) was intravenously injected weekly for 4 weeks. (500 μg/kg) subcutaneously daily Eight euthanized. Serum urine parameters, kidney histopathological injury scores, immunohistochemistry protein expressions measured. Results Blood glucose, creatinine, blood urea nitrogen albumin significantly elevated rats. Any single treatment markedly reduced their levels, yet combined decreased them further. monotherapy decrease renal score positive percentage, although the most prominent change displayed combinational therapy. Western blot showed expression MK Anti-MK suppressed significantly. The serum concentrations transforming factor-β1 connective tissue between therapy significant. Conclusions demonstrated that gene suppressing synergistically attenuates may provide a novel avenue designing future therapeutic regimens against DN.